Editas Medicine, Inc. EDIT has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.The company is evaluating EDIT-101 in the phase I/II BRILLIANCE study. Initial data from the same were announced in September 2021. Early observations from subjects treated in the mid-dose cohort of the study demonstrated clinical evidence of gene editing led by visual improvements.Editas plans to complete dosing in the adult high-dose and pediatric mid-dose cohorts in the first half of 2022.Shares of Editas have plunged 72.2% in the past year compared with the industry’s decrease of 35.1%.Image Source: Zacks Investment ResearchEditas’ other pipeline candidates are also progressing well. The company is evaluating the safety and efficacy of EDIT-301 for treating sickle cell disease (“SCD”). It is currently enrolling participants in the phase I/II RUBY study and expects to begin dosing in the first half of 2022.In December 2021, the FDA cleared the investigational new drug application for EDIT-301 to treat transfusion-dependent beta thalassemia (“TDT”). The company plans to begin clinical studies on EDIT-301 in TDT patients later in the ongoing year.Editas currently has no approved product in its portfolio. Therefore, successful development of EDIT-101, along with other pipeline candidates, remains in key focus for the company. Moreover, Editas’ pipeline candidates are in early-stage development and years away from commercialization. Hence, any regulatory setback for the pipeline candidates will be a significant impediment for the company.Meanwhile, stiff competition remains a headwind as several other companies, including CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA, are engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.CRISPR Therapeutics’ lead candidate, CTX001, a CRISPR gene-edited therapy, is being developed for treating SCD and TDT. CRISPR Therapeutics expects to file regulatory submission for CTX001 in both indications by 2022-end.Intellia Therapeutics is developing NTLA-2001, its lead program in vivo genome editing candidate, as a curative treatment for transthyretin amyloidosis. NTLA-2001 was the first candidate in Intellia Therapeutics’ pipeline to enter clinical development.Editas Medicine, Inc. Price and Consensus Editas Medicine, Inc. price-consensus-chart | Editas Medicine, Inc. QuoteZacks Rank & Stock to ConsiderEditas currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the biotech sector is AnaptysBio, Inc. ANAB, which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.AnaptysBio’s loss per share estimates have narrowed 0.3% for 2022, over the past 60 days. The stock has rallied 25.3% in the past year.AnaptysBio’s earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.3% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report AnaptysBio, Inc. (ANAB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research